Arrowhead Pharmaceuticals to Host R&D Day on RNAi-Based Therapies

Home/Newsroom/

Arrowhead Pharmaceuticals to Host...

PASADENA, Calif.–(BUSINESS WIRE)–

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it

will host a Research & Development Day to discuss its pipeline of

RNAi-based therapies on September 14 in New York City.

The R&D Day will feature presentations by key opinion leaders (KOLs)

Jeffrey Teckman, MD (St. Louis University School of Medicine), Stephen

Locarnini, PhD (Victorian Infectious Diseases Reference Laboratory), and

Ira Goldberg, MD (NYU Langone Medical Center), who will discuss the

current treatment landscape and unmet medical need for patients with

alpha-1 liver disease, hepatitis B (HBV), and cardiovascular disease,

respectively.

Arrowhead’s management team will provide an overview of the Company’s

new platform technology and its pipeline of RNAi-based therapeutics.

Discussion topics will include:

  • The Targeted RNAi Molecule (TRiM) Platform, which includes delivery

    targeted to the liver, tumors, and another tissue to be disclosed at

    the event

  • ARO-AAT for liver disease associated with alpha-1 antitrypsin

    deficiency

  • ARO-HBV for chronic hepatitis B infection

  • ARO-APOC3 for cardiovascular diseases

  • Updates on Arrowhead’s clinical development timelines

This event is intended for institutional investors, sell-side analysts,

investment bankers, and business development professionals only. Please

RSVP in advance if you plan to attend, as space is limited. To reserve a

seat, email or contact LifeSci Advisors, LLC at Mac@LifeSciAdvisors.com.

A live and archived webcast of the event, with slides, will be available

on Arrowhead’s website at http://ir.arrowheadpharma.com/events.cfm.

About the KOLs

Jeffrey H. Teckman, MD serves as Director, Division of Gastroenterology

and Hepatology, Department of Pediatrics and Professor of Pediatrics,

Biochemistry and Molecular Biology at St. Louis University School of

Medicine. Dr. Teckman also serves as the Scientific Advisor of The

Alpha-1 Project, Inc. and as the Director of Gastroenterology and

Hepatology at Cardinal Glennon Children’s Medical Center in Saint Louis,

Missouri. Dr. Teckman is a consultant to the pharmaceutical industry for

projects on drug safety and drug development and is involved in patient

advocacy for genetic disease anti-discrimination efforts. He is a

volunteer and patient educator for the American Liver Foundation and the

Alpha-1 Foundation. He has been involved in research on Alpha-1

Antitrypsin Deficiency and other liver diseases for 25 years. Dr.

Teckman’s work has been recognized with awards for research, patient

care and service, including the Miles and Shirley Fiterman Basic

Research Award in Gastroenterology and Best Doctors in America.

Professor Stephen Locarnini, BSc, (Hons), PhD, MBBS, FRC (Path) is the

Head of Research & Molecular Development at Victorian Infectious

Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital

Laboratory). He is also Director of World Health Organization (WHO)

Regional Reference Laboratory for Hepatitis B. His current major

research interests include viral hepatitis, hepatitis vaccines, and

antiviral chemotherapy with an emphasis on the basic virology of the

various agents of hepatitis, the molecular pathogenesis of hepatitis, as

well as prevention and public health control measures. The treatment of

hepatitis B and C infections with antiviral agents represents a major

focus. Professor Locarnini is the recipient of numerous awards including

the Malaysian Liver Foundation Medal for work on Viral Hepatitis, the

Bristol Myers Squibb Freedom to Discover Award and is the 2011 recipient

of the European Association for the Study of the Liver (EASL) award for

Scientific Recognition. He is author of over 200 peer-reviewed articles,

15 invited editorials and over 70 book chapters and reviews and every

year for the past 5 years, has delivered a number of invited and plenary

lectures at major international conferences. Professor Locarnini has

recently co-founded the NGO, Coalition to Eradicate Viral Hepatitis in

Asia-Pacific (CEVHAP).

Ira Goldberg, MD is currently the Chief of the Division of

Endocrinology, Diabetes and Metabolism at New York University Langone

School of Medicine. Dr. Goldberg has published over 200 articles. These

include written numerous book chapters, editorials, and reviews. He is

an associate editor of both the Journal of Lipid Research and Journal of

Clinical Lipidology. Dr. Goldberg’s research has focused on

abnormalities of lipoprotein metabolism, macrovascular disease in

diabetes, and the role of triglycerides in atherosclerosis. He has

received grant support in a number of investigational studies that

involve atherogenicity of apolipoprotein B-containing lipoproteins,

regulation of plasma triglyceride by lipase enzymes, diabetic

macrovascular disease, and lipid uptake and toxicity in the heart. Among

Dr. Goldberg’s honors is a MERIT Award from the National Heart, Lung,

and Blood Institute. He has previously served as chair of the NIH

Metabolism and CADO (cellular aspects of diabetes and obesity) study

sections.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable

diseases by silencing the genes that cause them. Using a broad portfolio

of RNA chemistries and efficient modes of delivery, Arrowhead therapies

trigger the RNA interference mechanism to induce rapid, deep, and

durable knockdown of target genes. RNA interference, or RNAi, is a

mechanism present in living cells that inhibits the expression of a

specific gene, thereby affecting the production of a specific protein.

Arrowhead’s RNAi-based therapeutics leverage this natural pathway of

gene silencing.

For more information, please visit www.arrowheadpharma.com,

or follow us on Twitter @ArrowheadPharma.

To be added to the Company’s email list and receive news directly,

please visit http://ir.arrowheadpharma.com/alerts.cfm.

Safe Harbor Statement under the Private Securities Litigation Reform

Act:

This news release contains forward-looking statements within the

meaning of the “safe harbor” provisions of the Private Securities

Litigation Reform Act of 1995. These statements are based upon our

current expectations and speak only as of the date hereof. Our actual

results may differ materially and adversely from those expressed in any

forward-looking statements as a result of various factors and

uncertainties, including the safety and efficacy of our product

candidates, the duration and impact of regulatory delays in our clinical

programs, our ability to finance our operations, the future success of

our scientific studies, our ability to successfully develop drug

candidates, the timing for starting and completing clinical trials,

rapid technological change in our markets, and the enforcement of our

intellectual property rights. Our most recent Annual Report on Form 10-K

and subsequent Quarterly Reports on Form 10-Q discuss some of the

important risk factors that may affect our business, results of

operations and financial condition. We assume no obligation to update or

revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
or
Investors

and Media:
LifeSci Advisors, LLC
Matthew P. Duffy
212-915-0685
matthew@lifesciadvisors.com
www.lifesciadvisors.com

Source: Arrowhead Pharmaceuticals, Inc.

News Provided by Acquire Media